论文部分内容阅读
目的:探讨CD80-IgG1Fc段融合蛋白修饰的HepG2细胞对淋巴细胞抗肿瘤免疫的影响。方法:应用福建省临床免疫研究所构建的CD80-IgG1Fc段融合蛋白,修饰肝癌细胞株HepG2细胞,用流式细胞术检测修饰的HepG2细胞上CD80的表达。将修饰的HepG2细胞与健康人外周血淋巴细胞混合后进行培养,分别应用MTT比色法、乳酸脱氢酶释放试验;检测经CD80-IgG1Fc段融合蛋白修饰的HepG2细胞对外周血淋巴细胞增殖及其细胞毒性的影响。结果:CD80-IgG1Fc段融合蛋白可有效地结合于HepG2细胞膜上,结合的量在一定范围内与融合蛋白的浓度呈正相关(P<0.05)。融合蛋白修饰的HepG2细胞可明显刺激外周血淋巴细胞活化增殖并增强CTL的细胞毒活性(P<0.05)。结论:CD80在抗肿瘤免疫中起着重要作用,用CD80-IgG1Fc段融合蛋白修饰的HepG2肿瘤细胞能明显增强淋巴细胞的特异性抗肿瘤免疫,为CD80用于肿瘤免疫治疗的研究提供了实验依据。
Objective: To investigate the effect of CD80-IgG1Fc fusion protein-modified HepG2 cells on anti-tumor immunity of lymphocytes. Methods: CD80-IgG1Fc fusion protein constructed by Institute of Clinical Immunology of Fujian Province was used to modify HepG2 cells. The expression of CD80 on modified HepG2 cells was detected by flow cytometry. The modified HepG2 cells were mixed with healthy human peripheral blood lymphocytes, MTT colorimetric assay and lactate dehydrogenase release assay were used respectively. HepG2 cells modified by CD80-IgG1Fc fusion protein were assayed for proliferation of peripheral blood lymphocytes and Its cytotoxic effects. Results: The fusion protein of CD80-IgG1Fc could bind to HepG2 cell membrane efficiently. The amount of fusion protein was positively correlated with the concentration of fusion protein in a certain range (P <0.05). HepG2 cells modified with fusion protein could obviously stimulate the activation and proliferation of peripheral blood lymphocytes and enhance the cytotoxic activity of CTL (P <0.05). Conclusion: CD80 plays an important role in anti-tumor immunity. HepG2 tumor cells modified with CD80-IgG1 Fc fusion protein can significantly enhance lymphocyte-specific anti-tumor immunity and provide experimental evidence for the study of CD80 on tumor immunotherapy .